Can ultrasound reveal how breathing machines affect ALS Patients' diaphragms?
NCT ID NCT07170865
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This pilot study will use ultrasound to measure diaphragm movement in 20 ALS patients, both while they breathe on their own and while using non-invasive ventilation (NIV). The goal is to see if ultrasound can detect changes in how the diaphragm works with and without the breathing support. This is an observational study, meaning no new treatment is being tested—just a new way of measuring an existing therapy.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors better monitor diaphragm function in ALS patients using ultrasound, potentially improving how and when non-invasive ventilation is used.
- What could go wrong
- This is a very small pilot study with only 20 people. It is observational, not testing a treatment, so it cannot directly change patient care. Results may not apply to all ALS patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 20 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2025
An estimate. Start dates often move.
- Expected to finish
-
Oct 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Diagnosis of bulbar or spinal amyotrophic lateral sclerosis (ALS) established by a neurologist
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adult patient (≥18 years old) * Diagnosis of bulbar or spinal amyotrophic lateral sclerosis (ALS) established by a neurologist * Indication for non-invasive ventilation (NIV) confirmed by the referring pulmonologist for daytime and/or nocturnal alveolar hypoventilation Exclusion Criteria: * Continuous (24-hour) non-invasive ventilation * Patient refusal to participate * Individual under legal guardianship or judicial protection
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Amyotrophic lateral sclerosis (ALS) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
CHU Grenoble-Alpes
Grenoble, Isère, 38043, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut bacteria may hold clues to dozens of diseases
- Can a magnetic helmet slow ALS? trial tests brain stimulation at home
- A chest belt that maps the lungs could help breathing machines fit better
- Could everyday antioxidants be a weapon against ALS?
- Can a new PET tracer light up the protein behind some dementias and ALS?
- Squeeze away anxiety: could a simple stress ball boost ventilation treatment success?